{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:55:45Z","timestamp":1790549745698,"version":"4.1.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12819-2","type":"journal-article","created":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:25:08Z","timestamp":1790501108000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lipidome as a ferroptotic rheostat in cholangiocarcinoma: A proposed model and its current evidence base"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7043-390X","authenticated-orcid":false,"given":"B\u00fc\u015fra","family":"K\u00f6se-Demirta\u015f","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duygu","family":"Kurto\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,27]]},"reference":[{"key":"12819_CR1","doi-asserted-by":"publisher","unstructured":"Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison B, Stockwell BR (2012) Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 149. https:\/\/doi.org\/10.1016\/j.cell.2012.03.042","DOI":"10.1016\/j.cell.2012.03.042"},{"key":"12819_CR2","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1152\/physrev.00031.2024","volume":"105","author":"J Zheng","year":"2025","unstructured":"Zheng J, Conrad M, WHEN METABOLISM MEETS FERROPTOSIS, CELL, DEATH (2025) Physiol Rev 105:651\u2013706. https:\/\/doi.org\/10.1152\/physrev.00031.2024","journal-title":"Physiol Rev"},{"key":"12819_CR3","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jhep.2022.04.038","volume":"77","author":"C Raggi","year":"2022","unstructured":"Raggi C, Taddei ML, Rae C, Braconi C, Marra F (2022) Metabolic reprogramming in cholangiocarcinoma. J Hepatol 77:849\u2013864. https:\/\/doi.org\/10.1016\/j.jhep.2022.04.038","journal-title":"J Hepatol"},{"key":"12819_CR4","doi-asserted-by":"publisher","unstructured":"Pant K, Richard S, Peixoto E, Gradilone SA (2020) Role of Glucose Metabolism Reprogramming in the Pathogenesis of Cholangiocarcinoma, Front. Med (Lausanne) 7. https:\/\/doi.org\/10.3389\/fmed.2020.00113","DOI":"10.3389\/fmed.2020.00113"},{"key":"12819_CR5","doi-asserted-by":"publisher","unstructured":"Qin H, Zheng G, Li Q, Shen L (2023) Metabolic reprogramming induced by DCA enhances cisplatin sensitivity through increasing mitochondrial oxidative stress in cholangiocarcinoma. Front Pharmacol 14. https:\/\/doi.org\/10.3389\/fphar.2023.1128312","DOI":"10.3389\/fphar.2023.1128312"},{"key":"12819_CR6","doi-asserted-by":"publisher","unstructured":"Liu CX, Wong CC-L (2026) Stratifying cholangiocarcinoma: tumor microenvironment, molecular drivers, and novel immunotherapeutic approaches. Clin Mol Hepatol 32. https:\/\/doi.org\/10.3350\/cmh.2025.0889","DOI":"10.3350\/cmh.2025.0889"},{"key":"12819_CR7","doi-asserted-by":"publisher","unstructured":"Zhao X, Zhang M, He J, Li X, Zhuang X (2024) Emerging insights into ferroptosis in cholangiocarcinoma (Review). Oncol Lett 28. https:\/\/doi.org\/10.3892\/ol.2024.14739","DOI":"10.3892\/ol.2024.14739"},{"key":"12819_CR8","doi-asserted-by":"publisher","unstructured":"Xu L, Zhang Y, Lin Z, Deng X, Ren X, Huang M, Li S, Zhou Q, Fang F, Yang Q, Zheng G, Chen Z, Wu Z, Sun X, Lin J, Shen J, Guo J, Li X, Xue T, Tan J, Lin X, Tan L, Peng H, Shen S, Peng S, Li S, Liang L, Cleary JM, Lai J, Xie Y, Kuang M (2024) FASN-mediated fatty acid biosynthesis remodels immune environment in Clonorchis sinensis infection-related intrahepatic cholangiocarcinoma. J Hepatol 81. https:\/\/doi.org\/10.1016\/j.jhep.2024.03.016","DOI":"10.1016\/j.jhep.2024.03.016"},{"key":"12819_CR9","doi-asserted-by":"publisher","unstructured":"Yu X, Tong H, Chen J, Tang C, Wang S, Si Y, Wang S, Tang Z (2023) CircRNA MBOAT2 promotes intrahepatic cholangiocarcinoma progression and lipid metabolism reprogramming by stabilizing PTBP1 to facilitate FASN mRNA cytoplasmic export. Cell Death Dis 14. https:\/\/doi.org\/10.1038\/s41419-022-05540-y","DOI":"10.1038\/s41419-022-05540-y"},{"key":"12819_CR10","doi-asserted-by":"publisher","first-page":"1477267","DOI":"10.3389\/fimmu.2024.1477267","volume":"15","author":"X Sun","year":"2024","unstructured":"Sun X, Zhao X, Wang S, Liu Q, Wei W, Xu J, Wang H, Yang W (2024) The pathological significance and potential mechanism of ACLY in cholangiocarcinoma. Front Immunol 15:1477267. https:\/\/doi.org\/10.3389\/fimmu.2024.1477267","journal-title":"Front Immunol"},{"key":"12819_CR11","doi-asserted-by":"publisher","unstructured":"Amontailak S, Titapun A, Jusakul A, Thanan R, Kimawaha P, Jamnongkan W, Thanee M, Sirithawat P, Techasen A (2024) Prognostic Values of Ferroptosis-Related Proteins ACSL4, SLC7A11, and CHAC1 in Cholangiocarcinoma. Biomedicines 12. https:\/\/doi.org\/10.3390\/biomedicines12092091","DOI":"10.3390\/biomedicines12092091"},{"key":"12819_CR12","doi-asserted-by":"publisher","unstructured":"Yin Z, Liu Q, Gao Y, Wang R, Qi Y, Wang D, Chen L, Yin X, He M, Li W (2024) GOLPH3 promotes tumor malignancy via inhibition of ferroptosis by upregulating SLC7A11 in cholangiocarcinoma. Mol Carcinog 63. https:\/\/doi.org\/10.1002\/mc.23697","DOI":"10.1002\/mc.23697"},{"key":"12819_CR13","doi-asserted-by":"publisher","unstructured":"Gupta G, Bhat AA, Goyal A, Singla N, Gupta S, Sharma S, Bhatt S, Dua K (2023) Exploring ACSL4\/LPCAT3\/ALOX15 and SLC7A11\/GPX4\/NFE2L2 as potential targets in ferroptosis-based cancer therapy. Future Med Chem 15. https:\/\/doi.org\/10.4155\/fmc-2023-0125","DOI":"10.4155\/fmc-2023-0125"},{"key":"12819_CR14","doi-asserted-by":"publisher","unstructured":"Yang M, Li M, Lyu Z, Yang Z (2023) Implication of Ferroptosis in Cholangiocarcinoma: A Potential Future Target? Cancer Manag Res 15. https:\/\/doi.org\/10.2147\/CMAR.S406150","DOI":"10.2147\/CMAR.S406150"},{"key":"12819_CR15","doi-asserted-by":"publisher","unstructured":"Sae-Fung A, Vinayavekhin N, Fadeel B, Jitkaew S (2024) ACSL3 is an unfavorable prognostic marker in cholangiocarcinoma patients and confers ferroptosis resistance in cholangiocarcinoma cells. NPJ Precis Oncol 8. https:\/\/doi.org\/10.1038\/s41698-024-00783-8","DOI":"10.1038\/s41698-024-00783-8"},{"key":"12819_CR16","doi-asserted-by":"publisher","unstructured":"Liu S, Fan S, Wang Y, Chen R, Wang Z, Zhang Y, Jiang W, Chen Y, Xu X, Yu Y, Li C, Li X (2023) ACSL4 serves as a novel prognostic biomarker correlated with immune infiltration in Cholangiocarcinoma. BMC Cancer 23. https:\/\/doi.org\/10.1186\/s12885-023-10903-5","DOI":"10.1186\/s12885-023-10903-5"},{"key":"12819_CR17","doi-asserted-by":"publisher","unstructured":"Wang TX, Liang JY, Zhang C, Xiong Y, Guan KL, Yuan HX (2019) The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis. Cell Death Dis 10. https:\/\/doi.org\/10.1038\/s41419-019-1984-4","DOI":"10.1038\/s41419-019-1984-4"},{"key":"12819_CR18","doi-asserted-by":"publisher","unstructured":"Lee CL, O\u2019Kane GM, Mason WP, Zhang WJ, Spiliopoulou P, Hansen AR, Grant RC, Knox JJ, Stockley TL, Zadeh G, Chen EX (2024) Circulating Oncometabolite 2-hydroxyglutarate as a Potential Biomarker for Isocitrate Dehydrogenase (IDH1\/2) Mutant Cholangiocarcinoma, Mol. Cancer Ther 23. https:\/\/doi.org\/10.1158\/1535-7163.MCT-23-0460","DOI":"10.1158\/1535-7163.MCT-23-0460"},{"key":"12819_CR19","doi-asserted-by":"publisher","unstructured":"Kagan VE, Mao G, Qu F, Angeli JPF, Doll S, Croix CS, Dar HH, Liu B, Tyurin VA, Ritov VB, Kapralov AA, Amoscato AA, Jiang J, Anthonymuthu T, Mohammadyani D, Yang Q, Proneth B, Klein-Seetharaman J, Watkins S, Bahar I, Greenberger J, Mallampalli RK, Stockwell BR, Tyurina YY, Conrad M, Baylr H (2017) Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol 13. https:\/\/doi.org\/10.1038\/nchembio.2238","DOI":"10.1038\/nchembio.2238"},{"key":"12819_CR20","doi-asserted-by":"publisher","unstructured":"Kastanek F, Spacilova M, Krystynik P, Dlaskova M, Solcova O (2023) Fenton Reaction\u2013Unique but Still Mysterious, Processes 11 https:\/\/doi.org\/10.3390\/pr11020432","DOI":"10.3390\/pr11020432"},{"key":"12819_CR21","doi-asserted-by":"publisher","unstructured":"He YJ, Liu XY, Xing L, Wan X, Chang X, Jiang HL (2020) Fenton reaction-independent ferroptosis therapy via glutathione and iron redox couple sequentially triggered lipid peroxide generator. Biomaterials 241. https:\/\/doi.org\/10.1016\/j.biomaterials.2020.119911","DOI":"10.1016\/j.biomaterials.2020.119911"},{"key":"12819_CR22","doi-asserted-by":"publisher","unstructured":"Yang WS, Sriramaratnam R, Welsch ME, Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji AF, Clish CB, Brown LM, Girotti AW, Cornish VW, Schreiber SL, Stockwell BR (2014) Regulation of ferroptotic cancer cell death by GPX4. Cell 156. https:\/\/doi.org\/10.1016\/j.cell.2013.12.010","DOI":"10.1016\/j.cell.2013.12.010"},{"key":"12819_CR23","doi-asserted-by":"publisher","unstructured":"Gaschler MM, Andia AA, Liu H, Csuka JM, Hurlocker B, Vaiana CA, Heindel DW, Zuckerman DS, Bos PH, Reznik E, Ye LF, Tyurina YY, Lin AJ, Shchepinov MS, Chan AY, Peguero-Pereira E, Fomich MA, Daniels JD, Bekish AV, Shmanai VV, Kagan VE, Mahal LK, Woerpel KA, Stockwell BR (2018) FINO2 initiates ferroptosis through GPX4 inactivation and iron oxidation. Nat Chem Biol 14. https:\/\/doi.org\/10.1038\/s41589-018-0031-6","DOI":"10.1038\/s41589-018-0031-6"},{"key":"12819_CR24","doi-asserted-by":"publisher","unstructured":"Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, Roberts MA, Tong B, Maimone TJ, Zoncu R, Bassik MC, Nomura DK, Dixon SJ, Olzmann JA (2019) The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature 575. https:\/\/doi.org\/10.1038\/s41586-019-1705-2","DOI":"10.1038\/s41586-019-1705-2"},{"key":"12819_CR25","doi-asserted-by":"publisher","unstructured":"Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, Irmler M, Beckers J, Aichler M, Walch A, Prokisch H, Tr\u00fcmbach D, Mao G, Qu F, Bayir H, F\u00fcllekrug J, Scheel CH, Wurst W, Schick JA, Kagan VE, Angeli JPF, Conrad M (2017) ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol 13. https:\/\/doi.org\/10.1038\/nchembio.2239","DOI":"10.1038\/nchembio.2239"},{"key":"12819_CR26","doi-asserted-by":"publisher","unstructured":"Zhao B, Li X, Wang Y, Shang P (2018) Iron-dependent cell death as executioner of cancer stem cells. J Experimental Clin Cancer Res 37. https:\/\/doi.org\/10.1186\/s13046-018-0733-3","DOI":"10.1186\/s13046-018-0733-3"},{"key":"12819_CR27","doi-asserted-by":"publisher","unstructured":"Chen J, Tang Y, Qin D, Yu X, Tong H, Tang C, Tang Z (2023) ALOX5 acts as a key role in regulating the immune microenvironment in intrahepatic cholangiocarcinoma, recruiting tumor-associated macrophages through PI3K pathway. J Transl Med 21. https:\/\/doi.org\/10.1186\/s12967-023-04804-1","DOI":"10.1186\/s12967-023-04804-1"},{"key":"12819_CR28","doi-asserted-by":"publisher","unstructured":"Qiu B, Zandkarimi F, Bezjian CT, Reznik E, Soni RK, Gu W, Jiang X, Stockwell BR (2024) Phospholipids with two polyunsaturated fatty acyl tails promote ferroptosis. Cell 187. https:\/\/doi.org\/10.1016\/j.cell.2024.01.030","DOI":"10.1016\/j.cell.2024.01.030"},{"key":"12819_CR29","doi-asserted-by":"publisher","unstructured":"Magtanong L, Ko PJ, To M, Cao JY, Forcina GC, Tarangelo A, Ward CC, Cho K, Patti GJ, Nomura DK, Olzmann JA (2019) Dixon, Exogenous Monounsaturated Fatty Acids Promote a Ferroptosis-Resistant Cell State. Cell Chem Biol 26. https:\/\/doi.org\/10.1016\/j.chembiol.2018.11.016","DOI":"10.1016\/j.chembiol.2018.11.016"},{"key":"12819_CR30","doi-asserted-by":"crossref","unstructured":"Kump A, Perne L, Koren \u0160, Jovi\u010di\u0107 EJ, Fegu\u0161 N, Kozmus CP, W\u00f6lk M, Brejchova K, Fedorova M, Kuda O, Petan T (2025) A Dual Role for DGAT-mediated Lipid Droplet Biogenesis in Ferroptosis Regulation, BioRxiv","DOI":"10.1101\/2025.05.21.655263"},{"key":"12819_CR31","doi-asserted-by":"publisher","unstructured":"Zou Y, Li H, Graham ET, Deik AA, Eaton JK, Wang W, Sandoval-Gomez G, Clish CB, Doench JG, Schreiber SL (2020) Cytochrome P450 oxidoreductase contributes to phospholipid peroxidation in ferroptosis. Nat Chem Biol 16. https:\/\/doi.org\/10.1038\/s41589-020-0472-6","DOI":"10.1038\/s41589-020-0472-6"},{"key":"12819_CR32","doi-asserted-by":"publisher","unstructured":"Bartolacci C, Andreani C, Vale G, Berto S, Melegari M, Crouch AC, Baluya DL, Kemble G, Hodges K, Starrett J, Politi K, Starnes SL, Lorenzini D, Raso MG, Solis Soto LM, Behrens C, Kadara H, Gao B, Wistuba II, Minna JD, McDonald JG, Scaglioni PP (2022) Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer. Nat Commun 13. https:\/\/doi.org\/10.1038\/s41467-022-31963-4","DOI":"10.1038\/s41467-022-31963-4"},{"key":"12819_CR33","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/s41556-024-01405-y","volume":"26","author":"Z Li","year":"2024","unstructured":"Li Z, Hu Y, Zheng H, Li M, Liu Y, Feng R, Li X, Zhang S, Tang M, Yang M, Yu R, Xu Y, Liao X, Chen S, Qian W, Zhang Q, Tang D, Li B, Song L, Li J (2024) LPCAT1-mediated membrane phospholipid remodelling promotes ferroptosis evasion and tumour growth. Nat Cell Biol 26:811\u2013824. https:\/\/doi.org\/10.1038\/s41556-024-01405-y","journal-title":"Nat Cell Biol"},{"key":"12819_CR34","doi-asserted-by":"publisher","unstructured":"Qiu C, Xiang Y-K, Da X-B, Zhang H-L, Kong X-Y, Hou N-Z, Zhang C, Tian F-Z, Yang Y-L (2024) Phospholipase A2 enzymes PLA2G2A and PLA2G12B as potential diagnostic and prognostic biomarkers in cholangiocarcinoma. World J Gastrointest Surg 16. https:\/\/doi.org\/10.4240\/wjgs.v16.i2.289","DOI":"10.4240\/wjgs.v16.i2.289"},{"key":"12819_CR35","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1186\/s12944-024-02298-4","volume":"23","author":"Y Bi","year":"2024","unstructured":"Bi Y, Ying X, Chen W, Wu J, Kong C, Hu W, Fang S, Yu J, Zhai M, Jiang C, Chen M, Shen L, Ji J, Tu J (2024) Glycerophospholipid-driven lipid metabolic reprogramming as a common key mechanism in the progression of human primary hepatocellular carcinoma and cholangiocarcinoma. Lipids Health Dis 23:326. https:\/\/doi.org\/10.1186\/s12944-024-02298-4","journal-title":"Lipids Health Dis"},{"key":"12819_CR36","doi-asserted-by":"publisher","unstructured":"Rodencal J, Dixon SJ (2023) A tale of two lipids: Lipid unsaturation commands ferroptosis sensitivity. Proteomics 23. https:\/\/doi.org\/10.1002\/pmic.202100308","DOI":"10.1002\/pmic.202100308"},{"key":"12819_CR37","doi-asserted-by":"publisher","unstructured":"Liu X, Sun Y, Lv X, Song M, Sun J, Sun Y (2024) Targeting lipid peroxidation-associated ferroptosis suppresses lung carcinoma progression by regulating cell cycle arrest. Int Immunopharmacol 138. https:\/\/doi.org\/10.1016\/j.intimp.2024.112518","DOI":"10.1016\/j.intimp.2024.112518"},{"key":"12819_CR38","doi-asserted-by":"publisher","unstructured":"Zhao N, Tan H, Wang L, Han L, Cheng Y, Feng Y, Li T, Liu X (2021) Palmitate induces fat accumulation via repressing FoxO1-mediated ATGL-dependent lipolysis in HepG2 hepatocytes. PLoS ONE 16. https:\/\/doi.org\/10.1371\/journal.pone.0243938","DOI":"10.1371\/journal.pone.0243938"},{"key":"12819_CR39","doi-asserted-by":"publisher","unstructured":"Li Y, Wang X, Yin X, Zhu X, Cui W, Dong L, Xia Y, Wang Y, Liu L, Zheng P, Tang Y (2026) PLIN5 deficiency ameliorates metabolic dysfunction-associated fatty liver disease by inhibiting ferroptosis. Mol Med Rep 33. https:\/\/doi.org\/10.3892\/mmr.2025.13714","DOI":"10.3892\/mmr.2025.13714"},{"key":"12819_CR40","doi-asserted-by":"publisher","unstructured":"Sae-fung A, Mutirangura A, Jitkaew S (2023) Identification and validation of a novel ferroptosis-related gene signature for prognosis and potential therapeutic target prediction in cholangiocarcinoma. Front Immunol 13. https:\/\/doi.org\/10.3389\/fimmu.2022.1051273","DOI":"10.3389\/fimmu.2022.1051273"},{"key":"12819_CR41","doi-asserted-by":"publisher","unstructured":"Wang X, Xu X, Jia R, Xu Y, Hu P (2025) UPLC-Q-TOF-MS-based unbiased serum metabolomics investigation of cholangiocarcinoma. Front Mol Biosci 12. https:\/\/doi.org\/10.3389\/fmolb.2025.1549223","DOI":"10.3389\/fmolb.2025.1549223"},{"key":"12819_CR42","doi-asserted-by":"publisher","unstructured":"Jackson LE, Tomlinson JL, Alva-Ruiz R, Gregory LA, Byeon SK, Abdelrahman AM, Mun DG, Grant CW, Fogarty ZC, Wang C, Roberts LR, Graham RP, Borad MJ, Ilyas SI, Gores GJ, Pandey A, Athreya AP, Smoot RL (2024) Metabolome-wide association identifies altered metabolites and metabolic pathways in the serum of patients with cholangiocarcinoma. JHEP Rep 6. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101068","DOI":"10.1016\/j.jhepr.2024.101068"},{"key":"12819_CR43","doi-asserted-by":"publisher","first-page":"12782","DOI":"10.1038\/s41598-025-97641-9","volume":"15","author":"P Prajumwongs","year":"2025","unstructured":"Prajumwongs P, Titapun A, Thanasukarn V, Jareanrat A, Khuntikeo N, Namwat N, Klanrit P, Wangwiwatsin A, Chindaprasirt J, Koonmee S, Sa-Ngiamwibool P, Muangritdech N, Roytrakul S, Loilome W (2025) Identification of serum metabolite biomarkers and metabolic reprogramming mechanisms to predict recurrence in cholangiocarcinoma. Sci Rep 15:12782. https:\/\/doi.org\/10.1038\/s41598-025-97641-9","journal-title":"Sci Rep"},{"key":"12819_CR44","doi-asserted-by":"publisher","unstructured":"An Y, Song H, Qiu H, Jiang J, Shi J (2025) Lipid Metabolism in Gastrointestinal Malignancies: Exploring Dysregulation, Biomarkers, and Treatment Strategies. Cancer Med 14. https:\/\/doi.org\/10.1002\/cam4.70975","DOI":"10.1002\/cam4.70975"},{"key":"12819_CR45","doi-asserted-by":"publisher","unstructured":"Safari MH, Rahimzadeh P, Alaei E, Alimohammadi M, Esfandiari N, Daneshi S, Malgard N, Farahani N, Taheriazam A, Hashemi M (2025) Targeting ferroptosis in gastrointestinal tumors: Interplay of iron-dependent cell death and autophagy. Mol Cell Probes 79. https:\/\/doi.org\/10.1016\/j.mcp.2025.102013","DOI":"10.1016\/j.mcp.2025.102013"},{"key":"12819_CR46","doi-asserted-by":"publisher","unstructured":"Zhang J, Ruan K, Chu Z, Wang X, Gu Y, Jin H, Zhang X, Liu Q, Yang J (2025) Reprogramming of fatty acid metabolism: a hidden force regulating the occurrence and progression of cholangiocarcinoma. Cell Death Discov 11. https:\/\/doi.org\/10.1038\/s41420-025-02351-w","DOI":"10.1038\/s41420-025-02351-w"},{"key":"12819_CR47","doi-asserted-by":"publisher","unstructured":"Duan Y, Deng M, Liu B, Meng X, Liao J, Qiu Y, Wu Z, Lin J, Dong Y, Duan Y, Sun Y (2024) Mitochondria targeted drug delivery system overcoming drug resistance in intrahepatic cholangiocarcinoma by reprogramming lipid metabolism. Biomaterials 309. https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122609","DOI":"10.1016\/j.biomaterials.2024.122609"},{"key":"12819_CR48","doi-asserted-by":"publisher","unstructured":"Pan Y, Zhang N, Fu X, Wang X, Ma Y, Chen Q, Zhou Y, Liu H, Zhu Y, Xu L, Wang Q, Chen D, Wang Z, Wang L (2025) Pharmacological induction of acetyl-CoA carboxylase 1 autophagic degradation attenuates lipid accumulation and cholangiocarcinoma progression. J Experimental Clin Cancer Res 44. https:\/\/doi.org\/10.1186\/s13046-025-03564-8","DOI":"10.1186\/s13046-025-03564-8"},{"key":"12819_CR49","doi-asserted-by":"publisher","unstructured":"Huang T, Cao H, Liu C, Sun X, Dai S, Liu L, Wang Y, Guo C, Wang X, Gao Y, Tang W, Xia Y (2024) MAL2 reprograms lipid metabolism in intrahepatic cholangiocarcinoma via EGFR\/SREBP-1 pathway based on single-cell RNA sequencing. Cell Death Dis 15. https:\/\/doi.org\/10.1038\/s41419-024-06775-7","DOI":"10.1038\/s41419-024-06775-7"},{"key":"12819_CR50","doi-asserted-by":"publisher","unstructured":"Luis G, Godfroid A, Nishiumi S, Cimino J, Blacher S, Maquoi E, Wery C, Collignon A, Longuesp\u00e9e R, Montero-Ruiz L, Dassoul I, Maloujahmoum N, Pottier C, Mazzucchelli G, Depauw E, Bellahc\u00e8ne A, Yoshida M, Noel A, Sounni NE (2021) Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence. Redox Biol 43. https:\/\/doi.org\/10.1016\/j.redox.2021.102006","DOI":"10.1016\/j.redox.2021.102006"},{"key":"12819_CR51","doi-asserted-by":"publisher","unstructured":"Sen U, Coleman C, Sen T (2023) Stearoyl coenzyme A desaturase-1: multitasker in cancer, metabolism, and ferroptosis. Trends Cancer 9. https:\/\/doi.org\/10.1016\/j.trecan.2023.03.003","DOI":"10.1016\/j.trecan.2023.03.003"},{"key":"12819_CR52","doi-asserted-by":"publisher","unstructured":"Liang JJ, Zhou XF, Long H, Li CY, Wei J, Yu XQ, Guo ZY, Zhou YQ, Deng ZS (2024) Recent advance of ATP citrate lyase inhibitors for the treatment of cancer and related diseases. Bioorg Chem 142. https:\/\/doi.org\/10.1016\/j.bioorg.2023.106933","DOI":"10.1016\/j.bioorg.2023.106933"},{"key":"12819_CR53","doi-asserted-by":"publisher","unstructured":"Lori G, Pastore M, Navari N, Piombanti B, Booijink R, Rovida E, Tusa I, Lewinska M, Andersen JB, Lottini T, Arcangeli A, Taddei ML, Pranzini E, Mancini C, Anceschi C, Madiai S, Sacco E, Rota S, Trapani A, Agrimi G, Ramazzotti M, Ostano P, Peraldo Neia C, Parri M, Carli F, Sabatini S, Gastaldelli A, Marra F, Raggi C (2024) Altered fatty acid metabolism rewires cholangiocarcinoma stemness features. JHEP Rep 6. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101182","DOI":"10.1016\/j.jhepr.2024.101182"},{"key":"12819_CR54","doi-asserted-by":"publisher","unstructured":"Gong Y, Chen L, Wang H, Zheng D, Li F, Wu C, Li Y, Deng Y, He Z, Yu C (2025) ANXA1 promotes intrahepatic cholangiocarcinoma proliferation and growth by regulating glutamine metabolism through GOT1 stabilization. J Experimental Clin Cancer Res 44. https:\/\/doi.org\/10.1186\/s13046-025-03400-z","DOI":"10.1186\/s13046-025-03400-z"},{"key":"12819_CR55","doi-asserted-by":"publisher","unstructured":"Hua S, Fei F, Li J, Liu Y, Gao Y, Wang X, Dong X, Liu Q, Yang J (2026) Amino acid metabolic reprogramming: future prospects for cholangiocarcinoma therapy. Cell Death Discov 12. https:\/\/doi.org\/10.1038\/s41420-025-02843-9","DOI":"10.1038\/s41420-025-02843-9"},{"key":"12819_CR56","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41575-019-0125-y","volume":"16","author":"JM Banales","year":"2019","unstructured":"Banales JM, Huebert RC, Karlsen T, Strazzabosco M, LaRusso NF, Gores GJ (2019) Cholangiocyte pathobiology. Nat Rev Gastroenterol Hepatol 16:269\u2013281. https:\/\/doi.org\/10.1038\/s41575-019-0125-y","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"12819_CR57","doi-asserted-by":"publisher","unstructured":"Ohigashi T, Kanno K, Sugiyama A, Nguyen PT, Kishikawa N, Otani Y, Kobayashi T, Matsuo H, Tazuma S (2019) Protective effect of phosphatidylcholine on lysophosphatidylcholine-induced cellular senescence in cholangiocyte. J Hepatobiliary Pancreat Sci 26. https:\/\/doi.org\/10.1002\/jhbp.684","DOI":"10.1002\/jhbp.684"},{"key":"12819_CR58","doi-asserted-by":"publisher","unstructured":"Ding K, Liu C, Li L, Yang M, Jiang N, Luo S, Sun L (2023) Acyl-CoA synthase ACSL4: An essential target in ferroptosis and fatty acid metabolism. Chin Med J (Engl 136. https:\/\/doi.org\/10.1097\/CM9.0000000000002533","DOI":"10.1097\/CM9.0000000000002533"},{"key":"12819_CR59","doi-asserted-by":"publisher","unstructured":"Merkel M, Goebel B, Boll M, Adhikari A, Maurer V, Steinhilber D, Culmsee C (2023) Mitochondrial Reactive Oxygen Species Formation Determines ACSL4\/LPCAT2-Mediated Ferroptosis. Antioxidants 12. https:\/\/doi.org\/10.3390\/antiox12081590","DOI":"10.3390\/antiox12081590"},{"key":"12819_CR60","doi-asserted-by":"publisher","unstructured":"Alsaleh M, Barbera T, Reeves H, Cramp M, Ryder S, Gabra H, Nash K, Shen Y-L, Holmes E, Williams R (2019) Taylor-Robinson, Characterization of the urinary metabolic profile of cholangiocarcinoma in a United Kingdom population, Hepat. Med 11. https:\/\/doi.org\/10.2147\/hmer.s193996","DOI":"10.2147\/hmer.s193996"},{"key":"12819_CR61","doi-asserted-by":"publisher","unstructured":"Tschuck J, Theilacker L, Rothenaigner I, Wei\u00df SAI, Akdogan B, Lam VT, M\u00fcller C, Graf R, Brandner S, P\u00fctz C, Rieder T, Schmitt-Kopplin P, Vincendeau M, Zischka H, Schorpp K, Hadian K (2023) Farnesoid X receptor activation by bile acids suppresses lipid peroxidation and ferroptosis. Nat Commun 14. https:\/\/doi.org\/10.1038\/s41467-023-42702-8","DOI":"10.1038\/s41467-023-42702-8"},{"key":"12819_CR62","doi-asserted-by":"publisher","unstructured":"Zhang Z, Cai X, Gong Y, Gong A, Liao X, Gao J, Wang D (2025) SREBP1-SCD1 enhanced MUFAs Biosynthesis drives Nutrient Deprived Pancreatic cancer cell Ferroptosis Resistance. J Cancer 16. https:\/\/doi.org\/10.7150\/jca.114356","DOI":"10.7150\/jca.114356"},{"key":"12819_CR63","doi-asserted-by":"publisher","unstructured":"Xuan Y, Wang H, Yung MMH, Chen F, Chan WS, Chan YS, Tsui SKW, Ngan HYS, Chan KKL, Chan DW (2022) SCD1\/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells. Theranostics 12. https:\/\/doi.org\/10.7150\/thno.70194","DOI":"10.7150\/thno.70194"},{"key":"12819_CR64","doi-asserted-by":"publisher","unstructured":"Saisomboon S, Kariya R, Boonnate P, Sawanyawisuth K, Cha\u2019on U, Luvira V, Chamgramol Y, Pairojkul C, Seubwai W, Silsirivanit A, Wongkham S, Okada S, Jitrapakdee S, Vaeteewoottacharn K (2023) Diminishing acetyl-CoA carboxylase 1 attenuates CCA migration via AMPK-NF-\u03baB-snail axis, Biochim. Biophys Acta Mol Basis Dis 1869. https:\/\/doi.org\/10.1016\/j.bbadis.2023.166694","DOI":"10.1016\/j.bbadis.2023.166694"},{"key":"12819_CR65","doi-asserted-by":"publisher","unstructured":"Banales JM, Rodrigues PM, Aff\u00f2 S, Andersen JB, Aspichueta P, Boulter L, Bridgewater J, Calvisi DF, Cardenas A, Cardinale V, Carpino G, Coulouarn C, Dopazo C, Edeline J, Fabris L, Folseraas T, Forner A, Goeppert B, Heikenwalder M, Kendall TJ, Khan SA, Kl\u00fcmpen HJ, Koerkamp BG, Lamarca A, Lindsey S, Lleo A, Luedde T, Macias RIR, Morement H, Nault JC, Olaizola P, Perugorria MJ, Raggi C, Rimassa L, Saborowski A, Valle JW, Vithayathil M, Vogel A, Braconi C (2026) Cholangiocarcinoma 2026: status quo, unmet needs and priorities. Nat Rev Gastroenterol Hepatol 23. https:\/\/doi.org\/10.1038\/s41575-025-01153-w","DOI":"10.1038\/s41575-025-01153-w"},{"key":"12819_CR66","doi-asserted-by":"publisher","unstructured":"Rizzo A, Ricci AD, Brandi G (2021) IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver? Cancer Treat. Res Commun 27. https:\/\/doi.org\/10.1016\/j.ctarc.2021.100356","DOI":"10.1016\/j.ctarc.2021.100356"},{"key":"12819_CR67","doi-asserted-by":"publisher","unstructured":"Sarcognato S, Sacchi D, Fabris L, Zanus G, Gringeri E, Niero M, Gallina G, Guido M (2022) Ferroptosis in Intrahepatic Cholangiocarcinoma: IDH1105GGT Single Nucleotide Polymorphism Is Associated With Its Activation and Better Prognosis. Front Med (Lausanne) 9. https:\/\/doi.org\/10.3389\/fmed.2022.886229","DOI":"10.3389\/fmed.2022.886229"},{"key":"12819_CR68","doi-asserted-by":"publisher","unstructured":"Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY, Guan KL, Zhao SM, Xiong Y (2011) Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases. Cancer Cell 19. https:\/\/doi.org\/10.1016\/j.ccr.2010.12.014","DOI":"10.1016\/j.ccr.2010.12.014"},{"key":"12819_CR69","doi-asserted-by":"publisher","unstructured":"Raggi C, Gammella E, Correnti M, Buratti P, Forti E, Andersen JB, Alpini G, Glaser S, Alvaro D, Invernizzi P, Cairo G, Recalcati S (2017) Dysregulation of Iron Metabolism in Cholangiocarcinoma Stem-like Cells. Sci Rep 7. https:\/\/doi.org\/10.1038\/s41598-017-17804-1","DOI":"10.1038\/s41598-017-17804-1"},{"key":"12819_CR70","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2026.2656779","author":"D Chen","year":"2026","unstructured":"Chen D, Jiang X, Duan T, Tian Y, Zhang J, Wang X, Tan J (2026) NCOA4-mediated ferritinophagy: emerging role and novel therapeutic target in precision oncology. Autophagy. https:\/\/doi.org\/10.1080\/15548627.2026.2656779","journal-title":"Autophagy"},{"key":"12819_CR71","doi-asserted-by":"publisher","unstructured":"Santana-Codina N, Mancias JD (2018) The role of NCOA4-mediated ferritinophagy in health and disease. Pharmaceuticals 11. https:\/\/doi.org\/10.3390\/ph11040114","DOI":"10.3390\/ph11040114"},{"key":"12819_CR72","unstructured":"Kalayci GOG (2025) Investigation of NCOA4-mediated ferritinophagy in cholangiocarcinoma cell line. FEBS OPEN BIO 15"},{"key":"12819_CR73","doi-asserted-by":"publisher","unstructured":"Koppula P, Zhuang L, Gan B (2021) Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell 12. https:\/\/doi.org\/10.1007\/s13238-020-00789-5","DOI":"10.1007\/s13238-020-00789-5"},{"key":"12819_CR74","doi-asserted-by":"publisher","unstructured":"Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I, Grocin AG, Xavier da Silva TN, Panzilius E, Scheel CH, Mour\u00e3o A, Buday K, Sato M, Wanninger J, Vignane T, Mohana V, Rehberg M, Flatley A, Schepers A, Kurz A, White D, Sauer M, Sattler M, Tate EW, Schmitz W, Schulze A, O\u2019Donnell V, Proneth B, Popowicz GM, Pratt DA, Angeli JPF, Conrad M (2019) FSP1 is a glutathione-independent ferroptosis suppressor. Nature 575. https:\/\/doi.org\/10.1038\/s41586-019-1707-0","DOI":"10.1038\/s41586-019-1707-0"},{"key":"12819_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-025-01589-5","author":"FY Liu","year":"2025","unstructured":"Liu FY, Yang YJ, Wang XL, Hong Y, Ou-Yang XP, Chang L, Zhu NL, Huang A, Zhang MM, Liu J, Geng MY, Shen AJ (2025) Ginsenoside (20)S-APPT induces ferroptosis in hepatocellular carcinoma and cholangiocarcinoma by targeting FSP1. Acta Pharmacol Sin. https:\/\/doi.org\/10.1038\/s41401-025-01589-5","journal-title":"Acta Pharmacol Sin"},{"key":"12819_CR76","doi-asserted-by":"publisher","unstructured":"Berndt C, Alborzinia H, Amen VS, Ayton S, Barayeu U, Bartelt A, Bayir H, Bebber CM, Birsoy K, B\u00f6ttcher JP, Brabletz S, Brabletz T, Brown AR, Br\u00fcne B, Bulli G, Bruneau A, Chen Q, DeNicola GM, Dick TP, Dist\u00e9fano A, Dixon SJ, Engler JB, Esser-von Bieren J, Fedorova M, Friedmann Angeli JP, Friese MA, Fuhrmann DC, Garc\u00eda-S\u00e1ez AJ, Garbowicz K, G\u00f6tz M, Gu W, Hammerich L, Hassannia B, Jiang X, Jeridi A, Kang YP, Kagan VE, Konrad DB, Kotschi S, Lei P, Le Tertre M, Lev S, Liang D, Linkermann A, Lohr C, Lorenz S, Luedde T, Methner A, Michalke B, Milton AV, Min J, Mishima E, M\u00fcller S, Motohashi H, Muckenthaler MU, Murakami S, Olzmann JA, Pagnussat G, Pan Z, Papagiannakopoulos T, Pedrera Puentes L, Pratt DA, Proneth B, Ramsauer L, Rodriguez R, Saito Y, Schmidt F, Schmitt C, Schulze A, Schwab A, Schwantes A, Soula M, Spitzlberger B, Stockwell BR, Thewes L, Thorn-Seshold O, Toyokuni S, Tonnus W, Trumpp A, Vandenabeele P, Vanden Berghe T, Venkataramani V, Vogel FCE, von Karstedt S, Wang F, Westermann F, Wientjens C, Wilhelm C, W\u00f6lk M, Wu K, Yang X, Yu F (2024) Redox Biol 75 Y. Zou, M. Conrad, Ferroptosis in health and disease. https:\/\/doi.org\/10.1016\/j.redox.2024.103211","DOI":"10.1016\/j.redox.2024.103211"},{"key":"12819_CR77","doi-asserted-by":"publisher","unstructured":"Zhao S, Cao J, Liang R, Peng T, Wu S, Liu Z, Wu Y, Song L, Sun C, Liu Y, Gu J, Wang L, Zhu R, Wang W, Sun Y (2025) METTL16 suppresses ferroptosis in cholangiocarcinoma by promoting ATF4 via m6 A modification. Int J Biol Sci 21. https:\/\/doi.org\/10.7150\/ijbs.97886","DOI":"10.7150\/ijbs.97886"},{"key":"12819_CR78","doi-asserted-by":"publisher","unstructured":"Xu QC, Tien YC, Shi YH, Chen S, Zhu YQ, Huang XT, Huang CS, Zhao W, Yin XY (2022) METTL3 promotes intrahepatic cholangiocarcinoma progression by regulating IFIT2 expression in an m6A-YTHDF2-dependent manner. Oncogene 41. https:\/\/doi.org\/10.1038\/s41388-022-02185-1","DOI":"10.1038\/s41388-022-02185-1"},{"key":"12819_CR79","doi-asserted-by":"publisher","unstructured":"Sheng J, Zhu Y, Zhang C, Huang C, Meng Z (2024) METTL3 Promotes Intrahepatic Cholangiocarcinoma Progression by Enhancing S100A4 Expression in an m6A-Dependent Manner. J Biol Regul Homeost Agents 38. https:\/\/doi.org\/10.23812\/j.biol.regul.homeost.agents.20243809.466","DOI":"10.23812\/j.biol.regul.homeost.agents.20243809.466"},{"key":"12819_CR80","doi-asserted-by":"publisher","unstructured":"Cai J, Cui Z, Zhou J, Zhang B, Lu R, Ding Y, Hu H (2022) METTL3 promotes glycolysis and cholangiocarcinoma progression by mediating the m6A modification of AKR1B10. Cancer Cell Int 22. https:\/\/doi.org\/10.1186\/s12935-022-02809-2","DOI":"10.1186\/s12935-022-02809-2"},{"key":"12819_CR81","doi-asserted-by":"publisher","unstructured":"Putatunda V, Jusakul A, Roberts L, Wang XW (2025) Genetic, Epigenetic, and Microenvironmental Drivers of Cholangiocarcinoma. Am J Pathol 195. https:\/\/doi.org\/10.1016\/j.ajpath.2024.10.013","DOI":"10.1016\/j.ajpath.2024.10.013"},{"key":"12819_CR82","doi-asserted-by":"publisher","unstructured":"Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ (2018) Cholangiocarcinoma-evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 15. https:\/\/doi.org\/10.1038\/nrclinonc.2017.157","DOI":"10.1038\/nrclinonc.2017.157"},{"key":"12819_CR83","doi-asserted-by":"publisher","unstructured":"Wu Q, Ellis H, Siravegna G, Michel AG, Norden BL, de la Cruz FF, Balasooriya ER, Zhen Y, Silveira VS, Che J, Corcoran RB, Bardeesy N (2024) Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma. Clin Cancer Res 30. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1317","DOI":"10.1158\/1078-0432.CCR-23-1317"},{"key":"12819_CR84","doi-asserted-by":"publisher","unstructured":"Walden D, Eslinger C, Bekaii-Saab T (2022) Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions\/rearrangements, Therap. Adv Gastroenterol 15. https:\/\/doi.org\/10.1177\/17562848221115317","DOI":"10.1177\/17562848221115317"},{"key":"12819_CR85","doi-asserted-by":"publisher","first-page":"7747","DOI":"10.2147\/CMAR.S330710","volume":"13","author":"M Salati","year":"2021","unstructured":"Salati M, Caputo F, Baldessari C, Carotenuto P, Messina M, Caramaschi S, Dominici M, Bonetti LR (2021) The evolving role of fgfr2 inhibitors in intrahepatic cholangiocarcinoma: From molecular biology to clinical targeting. Cancer Manag Res 13:7747\u20137757. https:\/\/doi.org\/10.2147\/CMAR.S330710","journal-title":"Cancer Manag Res"},{"key":"12819_CR86","doi-asserted-by":"publisher","unstructured":"Bray A, Sahai V, Mutant Cholangiocarcinoma IDH (2025) Pathogenesis, Management, and Future Therapies. Curr Oncol 32. https:\/\/doi.org\/10.3390\/curroncol32010044","DOI":"10.3390\/curroncol32010044"},{"key":"12819_CR87","doi-asserted-by":"publisher","unstructured":"Ma S, Ma Y, Qi F, Lei J, Chen F, Sun W, Wang D, Zhou S, Liu Z, Lu Z, Zhang D (2023) HSDL2 knockdown promotes the progression of cholangiocarcinoma by inhibiting ferroptosis through the P53\/SLC7A11 axis. World J Surg Oncol 21. https:\/\/doi.org\/10.1186\/s12957-023-03176-6","DOI":"10.1186\/s12957-023-03176-6"},{"key":"12819_CR88","doi-asserted-by":"publisher","unstructured":"Toshida K, Itoh S, Iseda N, Izumi T, Yoshiya S, Toshima T, Ninomiya M, Iwasaki T, Oda Y, Yoshizumi T (2024) Impact of TP53-induced glycolysis and apoptosis regulator on malignant activity and resistance to ferroptosis in intrahepatic cholangiocarcinoma. Cancer Sci 115. https:\/\/doi.org\/10.1111\/cas.15981","DOI":"10.1111\/cas.15981"},{"key":"12819_CR89","doi-asserted-by":"publisher","unstructured":"Hill MA, Alexander WB, Guo B, Kato Y, Patra K, O\u2019Dell MR, McCall MN, Whitney-Miller CL, Bardeesy N, Hezel AF (2018) Kras and Tp53 Mutations Cause Cholangiocyte- and Hepatocyte-Derived Cholangiocarcinoma. Cancer Res 78. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-1123","DOI":"10.1158\/0008-5472.CAN-17-1123"},{"key":"12819_CR90","doi-asserted-by":"publisher","unstructured":"Lee YR, Seo C, Abdullah M, Baek SH, Lee SJ (2025) Characterization of Differential GPX4 Essentiality Between Intrahepatic and Extrahepatic Cholangiocarcinoma via Leveraging of a Large-Scale Functional Genomic Screen. Int J Mol Sci 26. https:\/\/doi.org\/10.3390\/ijms262411990","DOI":"10.3390\/ijms262411990"},{"key":"12819_CR91","doi-asserted-by":"publisher","unstructured":"Duan L, Chang Y, Dai J, Lu H, Zhao W, Shen Y, Lin J, Cai X (2025) Lipid metabolism orchestrates liver regeneration: an integrated metabolic network. J Transl Med 23. https:\/\/doi.org\/10.1186\/s12967-025-07232-5","DOI":"10.1186\/s12967-025-07232-5"},{"key":"12819_CR92","doi-asserted-by":"publisher","unstructured":"Lin CR, Chu TM, Luo A, Huang SJ, Chou HY, Lu MW, Wu JL (2019) Omega-3 polyunsaturated fatty acids suppress metastatic features of human cholangiocarcinoma cells by suppressing twist. J Nutr Biochem 74. https:\/\/doi.org\/10.1016\/j.jnutbio.2019.108245","DOI":"10.1016\/j.jnutbio.2019.108245"},{"key":"12819_CR93","doi-asserted-by":"publisher","unstructured":"Mortensen MS, Ruiz J, Watts JL (2023) Polyunsaturated Fatty Acids Drive Lipid Peroxidation during Ferroptosis. Cells 12. https:\/\/doi.org\/10.3390\/cells12050804","DOI":"10.3390\/cells12050804"},{"key":"12819_CR94","doi-asserted-by":"publisher","unstructured":"Sa-ngiamwibool P, Yoshinari K, Shizu R, Kongpetch S, Prawan A, Senggunprai L (2025) Expression and Prognostic Implication of the Nuclear Receptors Farnesoid X Receptor and Pregnane X Receptor in Human Cholangiocarcinoma. Cancer Diagnosis Prognosis 5. https:\/\/doi.org\/10.21873\/cdp.10467","DOI":"10.21873\/cdp.10467"},{"key":"12819_CR95","doi-asserted-by":"publisher","unstructured":"Perez MA, Clostio AJ, Houston IR, Ruiz J, Magtanong L, Dixon SJ, Watts JL (2022) Ether lipid deficiency disrupts lipid homeostasis leading to ferroptosis sensitivity. PLoS Genet 18. https:\/\/doi.org\/10.1371\/journal.pgen.1010436","DOI":"10.1371\/journal.pgen.1010436"},{"key":"12819_CR96","doi-asserted-by":"publisher","unstructured":"Zou Y, Henry WS, Ricq EL, Graham ET, Phadnis VV, Maretich P, Paradkar S, Boehnke N, Deik AA, Reinhardt F, Eaton JK, Ferguson B, Wang W, Fairman J, Keys HR, Dan\u010d\u00edk V, Clish CB, Clemons PA, Hammond PT, Boyer LA, Weinberg RA, Schreiber SL (2020) Plasticity of ether lipids promotes ferroptosis susceptibility and evasion. Nature 585. https:\/\/doi.org\/10.1038\/s41586-020-2732-8","DOI":"10.1038\/s41586-020-2732-8"},{"key":"12819_CR97","doi-asserted-by":"publisher","unstructured":"Li W, Liang L, Liu S, Yi H, Zhou Y (2023) FSP1: a key regulator of ferroptosis. Trends Mol Med 29. https:\/\/doi.org\/10.1016\/j.molmed.2023.05.013","DOI":"10.1016\/j.molmed.2023.05.013"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12819-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12819-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12819-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:02:06Z","timestamp":1790546526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12819-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,27]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12819"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12819-2","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,27]]},"assertion":[{"value":"25 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1636"}}